Treating a Co-existence of Hidradenitis Suppurativa and Psoriasis with Secukinumab: A Case Report

Abstract

Background: Hidradenitis suppurativa (HS) and psoriasis are chronic inflammatory diseases that may coexist and share IL-17–mediated pathogenic pathways. Secukinumab, an anti–IL-17A monoclonal antibody, is effective in psoriasis and has shown promise in HS. Case report: We report a 47-year-old man with annular pustular psoriasis (PASI 38, DLQI 16) and moderate HS (Hurley II). Previous treatments were ineffective. Secukinumab led to complete skin clearance (PASI 100 by week 8) and only one HS flare over 10 months. Discussion: Given the failure of previous therapies, secukinumab (300 mg weekly for 5 weeks, then monthly) was initiated. The patient achieved complete clearance (PASI 100) by week 8, with a significant improvement in quality of life (DLQI 2), and experienced only one mild HS flare over a 10-month follow-up. This dual efficacy reinforces the central role of IL-17 in the pathogenesis of both conditions and supports the use of secukinumab as a potential therapeutic option in coexisting HS and psoriasis. Conclusion: Recognizing This case highlights the effectiveness of secukinumab in treating both annular pustular psoriasis and hidradenitis suppurativa. IL-17 inhibitors may offer a valuable therapeutic strategy in patients with overlapping inflammatory dermatoses.